Acute Myeloid Leukemia Treatment Market to Witness Modest Growth by 2020

The value of the global Acute Myeloid Leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, says business intelligence provider GBI Research.

​The company’s latest report, Acute Myeloid Leukemia Therapeutics Market to 2020 – Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts, states that this growth, which will occur across eight major markets (the US, UK, Canada, Germany, France, Italy, Spain and Japan), is attributable to rising AML prevalence and the anticipated launches of five premium-priced drugs into a market dominated by generics.

​Promising novel treatments, CPX-351, midostaurin, quizartinib, StemEx and treosulfan, have demonstrated encouraging efficacy and safety benefits in small patient cohorts in early clinical trials. These drugs are expected to show similar positive results in later studies, resulting in their approval during the forecast period, following which they are expected to outcompete inferior drugs and increase treatment rates.

​Katie Noon, Analyst for GBI Research, says: “The current developmental pipeline for AML has a strong number of drug candidates in both the late and early stages, especially for an orphan indication.

​“While AML treatment is dominated by generic chemotherapeutic agents, which have been the treatment of choice for the past four decades, the pipeline dynamics now suggest a strong focus on targeted therapies. These are predominately small molecule inhibitors of serine threonine proteins kinases, immunological agents against tumor-associated antigens/genes, and antagonists against cell-surface receptors.”

​Despite the active pipeline, GBI Research states that increasing stem cell transplant rates, combined with a lack of standardized treatment and high disease heterogeneity, could decrease AML prevalence, therefore hindering the positive effects of new drug approvals and AML drug market expansion by 2020.

​Noon continues: “Significant developments in transplant methods and safety have made these procedures the most effective form of AML treatment across all patients. “A rise in stem cell transplants will allow for long-term remissions and higher recovery rates, lowering both AML prevalence and the demand for pharmacological therapeutics,” the analyst concludes.

​The report provides information on treatment usage patterns, marketed and pipeline drugs and market forecasts across indications for Acute Myeloid Leukemia (AML), covering eight major markets: the US, UK, Canada, Germany, France, Italy, Spain and Japan. The report includes in-depth analysis on drug combinations used in AML treatment, key market drivers and barriers, and licensing and co-development deals. It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts. GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com. Follow us online for the latest industry updates: Facebook | LinkedIn | Twitter